Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 47,586 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Rusckowski Duprey sold 47,586 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $813,720.60. Following the completion of the sale, the insider owned 226,057 shares of the company’s stock, valued at approximately $3,865,574.70. The trade was a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.06 on Wednesday, hitting $17.42. 2,004,364 shares of the company were exchanged, compared to its average volume of 4,402,927. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The company has a 50-day moving average price of $16.49 and a 200 day moving average price of $17.13. The stock has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, sell-side analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TAK has been the topic of a number of recent analyst reports. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership lifted its stake in Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after acquiring an additional 2,854,069 shares in the last quarter. UBS Group AG grew its holdings in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp lifted its holdings in Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after buying an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its position in Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after buying an additional 880,289 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.